EA200300481A1 - Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов - Google Patents

Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов

Info

Publication number
EA200300481A1
EA200300481A1 EA200300481A EA200300481A EA200300481A1 EA 200300481 A1 EA200300481 A1 EA 200300481A1 EA 200300481 A EA200300481 A EA 200300481A EA 200300481 A EA200300481 A EA 200300481A EA 200300481 A1 EA200300481 A1 EA 200300481A1
Authority
EA
Eurasian Patent Office
Prior art keywords
class
protease inhibitors
piranones
emulsing
compositions
Prior art date
Application number
EA200300481A
Other languages
English (en)
Other versions
EA006759B1 (ru
Inventor
Шерлинн Чень
Джоселин А. Ганн
Original Assignee
Бёрингер Ингельхайм Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фармасьютиклз, Инк. filed Critical Бёрингер Ингельхайм Фармасьютиклз, Инк.
Publication of EA200300481A1 publication Critical patent/EA200300481A1/ru
Publication of EA006759B1 publication Critical patent/EA006759B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)

Abstract

В заявке описана микроэмульсия ингибиторов протеазы из класса пиранонов, практически не содержащая спирта и пропиленгликоля, которая включает ингибитор протеазы из класса пиранонов, одно или несколько фармацевтически приемлемых поверхностно-активных веществ и растворитель, представляющий собой полиэтиленгликоль со средней молекулярной массой более 300, но менее 600, и липофильный компонент, содержащий моно- и диглицериды со средней длиной цепи, и необязательно основной амин.Отчет о международном поиске был опубликован 2003.05.08.
EA200300481A 2000-10-31 2001-10-30 Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов EA006759B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443400P 2000-10-31 2000-10-31
PCT/US2001/048683 WO2002036110A2 (en) 2000-10-31 2001-10-30 Oral self-emulsifying formulations of pyranone protease inhibitors

Publications (2)

Publication Number Publication Date
EA200300481A1 true EA200300481A1 (ru) 2003-10-30
EA006759B1 EA006759B1 (ru) 2006-04-28

Family

ID=22922748

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300481A EA006759B1 (ru) 2000-10-31 2001-10-30 Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов

Country Status (30)

Country Link
US (1) US6555558B2 (ru)
EP (1) EP1333810B1 (ru)
JP (1) JP4298998B2 (ru)
KR (1) KR100847679B1 (ru)
CN (1) CN1240437C (ru)
AT (1) ATE381922T1 (ru)
AU (2) AU3091802A (ru)
BG (1) BG107728A (ru)
BR (1) BR0114969A (ru)
CA (1) CA2424596C (ru)
CZ (1) CZ20031407A3 (ru)
DE (1) DE60132103T2 (ru)
DK (1) DK1333810T3 (ru)
EA (1) EA006759B1 (ru)
EC (1) ECSP034572A (ru)
EE (1) EE200300201A (ru)
ES (1) ES2298286T3 (ru)
HK (1) HK1060523A1 (ru)
HR (1) HRP20030339A2 (ru)
HU (1) HUP0301487A2 (ru)
IL (2) IL154983A0 (ru)
MX (1) MXPA03003795A (ru)
NO (1) NO20031909L (ru)
NZ (1) NZ526169A (ru)
PL (1) PL365627A1 (ru)
SK (1) SK6572003A3 (ru)
UA (1) UA78689C2 (ru)
WO (1) WO2002036110A2 (ru)
YU (1) YU32103A (ru)
ZA (1) ZA200302389B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070390A2 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
US7482939B2 (en) * 2005-11-15 2009-01-27 Roche Molecular Systems, Inc. Electrical drop surveillance
US20090196861A1 (en) * 2005-11-17 2009-08-06 Bioavailability, Inc. Biocompatible Latent Emulsifiers
US8277839B2 (en) * 2006-07-06 2012-10-02 Ares Trading S.A. Oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
JP2011504162A (ja) * 2007-05-23 2011-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用チプラナビルの自己乳化型製剤
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA116004C2 (uk) 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
EP3302429A1 (en) 2015-05-28 2018-04-11 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1033128T2 (sl) * 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
BR9810729B1 (pt) * 1997-07-29 2010-07-13 composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
ES2174462T3 (es) * 1997-07-29 2002-11-01 Upjohn Co Formulacion autoestimulante para compuestos lipofilos.
AU762349B2 (en) * 1998-11-04 2003-06-26 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir

Also Published As

Publication number Publication date
DK1333810T3 (da) 2008-02-04
IL154983A (en) 2006-12-31
ZA200302389B (en) 2004-04-23
BR0114969A (pt) 2003-12-09
KR20030048097A (ko) 2003-06-18
AU2002230918B2 (en) 2006-12-14
UA78689C2 (en) 2007-04-25
EP1333810A2 (en) 2003-08-13
NO20031909L (no) 2003-05-22
DE60132103D1 (de) 2008-02-07
DE60132103T2 (de) 2008-04-17
JP4298998B2 (ja) 2009-07-22
PL365627A1 (en) 2005-01-10
WO2002036110A9 (en) 2003-09-18
CN1471387A (zh) 2004-01-28
WO2002036110A3 (en) 2003-05-08
CA2424596C (en) 2010-06-29
CZ20031407A3 (cs) 2003-09-17
YU32103A (sh) 2006-05-25
AU3091802A (en) 2002-05-15
IL154983A0 (en) 2003-10-31
HK1060523A1 (en) 2004-08-13
US20020115690A1 (en) 2002-08-22
CN1240437C (zh) 2006-02-08
HRP20030339A2 (en) 2005-04-30
BG107728A (bg) 2004-01-30
JP2004512362A (ja) 2004-04-22
HUP0301487A2 (hu) 2003-11-28
MXPA03003795A (es) 2003-08-20
EE200300201A (et) 2003-08-15
NZ526169A (en) 2005-12-23
US6555558B2 (en) 2003-04-29
KR100847679B1 (ko) 2008-07-23
NO20031909D0 (no) 2003-04-29
ECSP034572A (es) 2003-05-26
CA2424596A1 (en) 2002-05-10
EA006759B1 (ru) 2006-04-28
WO2002036110A2 (en) 2002-05-10
ATE381922T1 (de) 2008-01-15
SK6572003A3 (en) 2003-10-07
EP1333810B1 (en) 2007-12-26
ES2298286T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
EA200300481A1 (ru) Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
EA199900749A1 (ru) Фармацевтическая композиция
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
RS49611B (sr) Ziprasidon formulacije
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
EA200300050A1 (ru) Гликопептидфосфонатные производные
EA200000873A1 (ru) Ингибиторы фосфолипазы a
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
EA200000768A1 (ru) ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
ES2180133T3 (es) N,n',n'''-tris(2,4-bis((1-hidrocarbiloxi-2,2,6,6-tetrametil-piperidin-4-il)alquilamino)-s-triacin-6-il)-3,3'-etilidendi-iminodipropilaminas, sus isomeros y derivados puenteados y composiciones polimericas estabilizadas con estas.
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
WO2001074331A1 (fr) Compositions huileuses contenant des medicaments solubles dans des graisses
NO324217B1 (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
AR032586A1 (es) Composicion farmaceutica
RU2001126719A (ru) Дигетерозамещенные ингибиторы металлопротеазы
EA200000320A1 (ru) Изохинолины в качестве ингибиторов урокиназы
ATE308548T1 (de) Glycerophosphoinositol-derivate als cytosolic a2 phospholipase modulatoren
NO20015892D0 (no) Inhibitorer av metallproteinaser
BR0110902A (pt) Inibidores de mmp-9/mmp-2
EA200100051A1 (ru) Ингибиторы fkbp
EA200400670A1 (ru) Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
EA200000859A1 (ru) Способ синтеза ингибиторов протеазы вич
AR028537A1 (es) Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis
HRP20080546T3 (en) Combination of an antagonist of the tp-receptors and clopidogrel

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU